Akari Therapeutics Plc (AKTX)

1.92 +0.06 (+3.226%)

IEX Real-Time Price

October 19, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 1.86

Price Open 1.89

Volume: 47,741

Avg Volume: 79,598

Market Cap: 29.29M

P/E Ratio -4.09

52 Wk Range 1.7-5.49



AKTX Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-09-28
13.94M
264,889
3.20
1.90%

2018-09-14
13.94M
264,242
4.42
1.90%

2018-08-31
13.94M
275,764
9.33
1.98%

2018-08-15
13.94M
293,339
11.64
2.10%




AKTX Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-17
Q2 2018
N/A
0.00 (0)
-0.28
0.00

2018-07-02
Q1 2018
N/A
0.00 (0)
0.00
0.00

2018-05-21
Q1 2018
N/A
-1.00 (1)
0.00
0.00

2018-03-30
Q4 2017
N/A
-1.00 (1)
-0.07
0.00

News

Akari Therapeutics reports Q2 results (2018-09-27 06:59 SeekingAlpha)

Akari Therapeutics (NASDAQ: AKTX ): Q2 GAAP EPS of -$0.01. More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more …

 


Statistics

Shares Outstanding: 15.26M

Top 15 Institution Percent: 9.20

Price To Sales: 283778.97

Price To Book: 3.29

Revenue: N/A

Gross Profit: N/A

Cash: 20.97M

Debt: N/A

Return On Assets: -129.57

Return On Equity: -202.39

Profit Margin: N/A

Price History

Beta: -6.59

50-day Moving Avg: 2.02

200-day Moving Avg: 2.19

YTD Change: -56.26

5-day Change: 7.87

1-month Change: -4.61

3-month Change: -8.13

6-month Change: -4.72

1-year Change: -57.33

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Akari Therapeutics Plc

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.akaritx.com

Akari Therapeutics PLC is a biopharmaceutical company in clinical stage. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system.